Elsevier

The Lancet

Volume 385, Issue 9975, 4–10 April 2015, Pages 1273-1275
The Lancet

Comment
The asthmas in 2015 and beyond: a Lancet Commission

https://doi.org/10.1016/S0140-6736(15)60654-7Get rights and content

First page preview

First page preview
Click to open first page preview

References (15)

There are more references available in the full text version of this article.

Cited by (27)

  • A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions

    2019, Value in Health
    Citation Excerpt :

    Very few studies covered all of the items that are required for others to reproduce the results. Contemporary asthma management is shifting its focus toward identifying and treating multiple traits in patients with asthma.70 The existing decision-analytic asthma models, however, seem to lack the granularity that will be required to properly model such precision medicine approaches to asthma management.

  • Adrenomedullin mediates pro-angiogenic and pro-inflammatory cytokines in asthma and COPD

    2019, Pulmonary Pharmacology and Therapeutics
    Citation Excerpt :

    Asthma and chronic obstructive pulmonary disease (COPD) are inflammatory lung diseases that cannot be cured by available drugs [1,2] and therefore, there is considerable interest to elucidate the causes and underlying mechanisms related to the systemic inflammatory processes in both diseases.

  • Health care costs and resource utilization for different asthma severity stages in Colombia: A claims data analysis

    2018, World Allergy Organization Journal
    Citation Excerpt :

    Even though severe asthma is not common, its contribution to total costs is high [10–13]. Despite some pharmacological advances and the divulgation of guidelines for diagnosis, treatment and prevention, asthma is still a global difficult-to-treat condition and the implementation of strategies for achieving better outcomes remains heterogeneous, especially in developing countries [14–18]. In Latin America, as in other developing regions in the world, several barriers exist to achieve asthma control [19–21].

  • Chronic obstructive pulmonary disease subpopulations and phenotyping

    2018, Journal of Allergy and Clinical Immunology
    Citation Excerpt :

    By enclosing different entities under the umbrella of COPD, we are committing our pathophysiologic investigations and therapeutic discoveries to fail because of multiple confounders. This is now increasingly accepted in asthmatic patients, in whom relabeling asthma and identification of treatable traits is at the forefront of current investigations.143-145 In patients with COPD, it is clear that novel endotyping approaches combined with small-airways physiologic evaluation and imaging are needed to define these different subpopulations of COPD.

View all citing articles on Scopus
View full text